Rita Banzi1, Chiara Gerardi2, Vittorio Bertele'2, Silvio Garattini2. 1. Laboratory of Regulatory Policies, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milan, Italy. Electronic address: rita.banzi@marionegri.it. 2. Laboratory of Regulatory Policies, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milan, Italy.
Abstract
PURPOSE: This paper examines conditional approvals that allow the marketing of medicines with unsettled benefit-risk profiles in the European Union. METHODS: We identified medicines that had received conditional approval from the European Medicines Agency in the period January 2006-June 2015. We searched the reasons and bases for approvals, the median time to address the specific obligations imposed in order to cover the information gap and allow regular authorisations, and their extent of fulfilment. RESULTS: Of the 26 products conditionally authorised two were withdrawn for commercial reasons, ten were switched to regular approval, and 14 are still under conditional approval. Conditional approval was granted mainly to medicinal products intended for seriously debilitating disease or life-threatening disease. The median time to address the specific obligations was four years (range 0.2 to 7.7). There were delays or discrepancies in the fulfilment of these obligations in more than one third of the authorisation procedures. CONCLUSIONS: In most cases there was limited evidence supporting the positive benefit-risk balance at the time of approval. Delays or discrepancies in the fulfilment of obligations allow medicinal products with unsettled benefit-risk profiles onto the market for several years. This should be taken into account when further early or step-wise licensing strategies are considered.
PURPOSE: This paper examines conditional approvals that allow the marketing of medicines with unsettled benefit-risk profiles in the European Union. METHODS: We identified medicines that had received conditional approval from the European Medicines Agency in the period January 2006-June 2015. We searched the reasons and bases for approvals, the median time to address the specific obligations imposed in order to cover the information gap and allow regular authorisations, and their extent of fulfilment. RESULTS: Of the 26 products conditionally authorised two were withdrawn for commercial reasons, ten were switched to regular approval, and 14 are still under conditional approval. Conditional approval was granted mainly to medicinal products intended for seriously debilitating disease or life-threatening disease. The median time to address the specific obligations was four years (range 0.2 to 7.7). There were delays or discrepancies in the fulfilment of these obligations in more than one third of the authorisation procedures. CONCLUSIONS: In most cases there was limited evidence supporting the positive benefit-risk balance at the time of approval. Delays or discrepancies in the fulfilment of obligations allow medicinal products with unsettled benefit-risk profiles onto the market for several years. This should be taken into account when further early or step-wise licensing strategies are considered.
Authors: Jarno Hoekman; Thea T Klamer; Aukje K Mantel-Teeuwisse; Hubert G M Leufkens; Marie L De Bruin Journal: Br J Clin Pharmacol Date: 2016-04-22 Impact factor: 4.335
Authors: Michael Ermisch; Anna Bucsics; Patricia Vella Bonanno; Francis Arickx; Alexander Bybau; Tomasz Bochenek; Marc van de Casteele; Eduardo Diogene; Jurij Fürst; Kristina Garuolienė; Martin van der Graaff; Jolanta Gulbinovič; Alan Haycox; Jan Jones; Roberta Joppi; Ott Laius; Irene Langner; Antony P Martin; Vanda Markovic-Pekovic; Laura McCullagh; Einar Magnusson; Ellen Nilsen; Gisbert Selke; Catherine Sermet; Steven Simoens; Robert Sauermann; Ad Schuurman; Ricardo Ramos; Vera Vlahovic-Palcevski; Corinne Zara; Brian Godman Journal: Front Pharmacol Date: 2016-09-28 Impact factor: 5.810
Authors: Patricia Vella Bonanno; Michael Ermisch; Brian Godman; Antony P Martin; Jesper Van Den Bergh; Liudmila Bezmelnitsyna; Anna Bucsics; Francis Arickx; Alexander Bybau; Tomasz Bochenek; Marc van de Casteele; Eduardo Diogene; Irene Eriksson; Jurij Fürst; Mohamed Gad; Ieva Greičiūtė-Kuprijanov; Martin van der Graaff; Jolanta Gulbinovic; Jan Jones; Roberta Joppi; Marija Kalaba; Ott Laius; Irene Langner; Ileana Mardare; Vanda Markovic-Pekovic; Einar Magnusson; Oyvind Melien; Dmitry O Meshkov; Guenka I Petrova; Gisbert Selke; Catherine Sermet; Steven Simoens; Ad Schuurman; Ricardo Ramos; Jorge Rodrigues; Corinne Zara; Eva Zebedin-Brandl; Alan Haycox Journal: Front Pharmacol Date: 2017-08-23 Impact factor: 5.810